Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Dexcom (DXCM) Cost of Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Cost of Revenue for 16 consecutive years, with $466.9 million as the latest value for Q4 2025.

  • Quarterly Cost of Revenue rose 2.01% to $466.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, up 16.64% year-over-year, with the annual reading at $1.9 billion for FY2025, 16.64% up from the prior year.
  • Cost of Revenue for Q4 2025 was $466.9 million at Dexcom, down from $477.9 million in the prior quarter.
  • The five-year high for Cost of Revenue was $477.9 million in Q3 2025, with the low at $161.1 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $329.2 million, with a median of $338.3 million recorded in 2023.
  • The sharpest move saw Cost of Revenue soared 43.2% in 2022, then increased 2.01% in 2025.
  • Over 5 years, Cost of Revenue stood at $225.6 million in 2021, then increased by 21.41% to $273.9 million in 2022, then surged by 37.97% to $377.9 million in 2023, then rose by 21.12% to $457.7 million in 2024, then rose by 2.01% to $466.9 million in 2025.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $466.9 million, $477.9 million, and $468.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.